A Prospective Institutional Study for the Treatment of Children With Newly Diagnosed Langerhans Cell Histiocytosis Using a Cytarabine Contained Protocol

What this Trial Is About

Researchers are evaluating treatment approaches for children newly diagnosed with Langerhans Cell Histiocytosis (LCH), a rare condition affecting various organs. This prospective study focuses on using a protocol that contains cytarabine, aiming to improve outcomes by adjusting treatment intensity and duration. The study divides patients into groups based on disease extent and risk organ involvement, building on previous findings about response rates and survival in children with multisystem LCH. Treatment varies by group: Patients with multisystem disease involving risk organs receive an initial 6-week therapy followed by 16 weeks of consolidation and 26 weeks of maintenance therapy including prednisone, cytarabine, vincristine, and mercaptopurine. Patients with multisystem disease without risk organ involvement get 6 weeks of initial therapy with cytarabine and 46 weeks of continuation therapy without cytarabine. Those with single system or special site involvement receive 6 weeks of initial treatment and 46 weeks of continuation without cytarabine. Patients with single system, unifocal disease receive local therapy followed by observation, with chemotherapy reserved for disease reactivation. Participants will be monitored through various evaluations including response rates at week 6 or 12 for those with risk organ involvement, and reactivation rates up to 5 years for all patients. Overall survival is also tracked for patients with risk organ involvement. The study involves clinical assessments, laboratory tests, and follow-up visits over several years to measure treatment effects and disease progression, with a total participation period extending up to five years.

A Prospective Study for the Treatment of Children With Newly Diagnosed LCH Using a Cytarabine Contained Protocol